| THE UNIVERSITY OF HONG KONG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120121634 | SOLUBLE PD-1 VARIANTS, FUSION CONSTRUCTS, AND USES THEREOF - The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In additon, the subject invention can be used in the prevention and/or treatment of tumor or cancer. | 05-17-2012 |
| 20120107317 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES - The subject invention provides novel uses of cytoplasmic c-Myc for modulation of innate immune responses. The invention is based, at least in part, on the surprising discovery that cytoplasmic c-Myc, instead of nuclear c-Myc, modulates pro-inflammatory immune responses via its role as a positive feedback regulator. Specifically, the subject invention provides methods for treatment or amelioration of inflammatory diseases and/or immune disorders via inhibition c-Myc expression or its activity. Also provided are methods for the development of therapeutic agents for treating infection, inflammation, immune diseases and autoimmune diseases. | 05-03-2012 |
| 20120055867 | DOPING OF INORGANIC MINERALS TO HYDROPHOBIC MEMBRANE SURFACE - Disclosed is a membrane surface modification method. The method is applicable to a variety of hydrophobic membranes by doping selected inorganic particles. One act of the method involves the in-situ embedment of the inorganic particles onto the membrane surface by dispersing the particles in a non-solvent bath for polymer precipitation. Further membrane surface modification can be achieved by hydrothermally growing new inorganic phase on the embedded particles. The embedment of particles is for the subsequent phase growth. | 03-08-2012 |
| 20120018711 | PLATINUM (II) TETRADENTATE ONCN COMPLEXES FOR ORGANIC LIGHT-EMITTING DIODE APPLICATIONS - Described are novel platinum (II) containing organometallic materials. These materials show green to orange emissions with high emission quantum efficiencies. Using the materials as emitting materials; pure green emitting organic light-emitting diodes can be fabricated. Since the novel platinum (II) containing organometallic materials are soluble in common solvents, solution process methods such as spin coating and printing can be used for device fabrication. | 01-26-2012 |
| 20110294872 | HIGH-AFFINITY NUCLEIC ACID APTAMERS AGAINST SCLEROSTIN PROTEIN - Described are nucleic acid aptamers that are able to bind to and inhibit the function of sclerostin, which is an important negative regulator of bone growth. The aptamers have application as therapeutics for diseases of bone including osteoporosis, osteopenia, osteoarthritis and other osteoporosis-related conditions and complications. | 12-01-2011 |
| 20110282065 | SOLID SUPPORTED GOLD NANOPARTICLES, METHODS OF USE THEREOF, AND METHODS FOR MAKING SAME - Solid-supported gold nanoparticles for use as a catalyst for the synthesis of quinolines from anilines and aldehydes using oxygen as an oxidant are provided. Also provided are a method for the preparation of SiO | 11-17-2011 |
| 20110280862 | GEP AND DRUG TRANSPORTER REGULATION, CANCER THERAPY AND PROGNOSIS - Described herein are methods for manipulating GEP and/or drug transporters (e.g., ABCB5 and/or ABCF1) on a cell, as well as related products. Also described herein are methods for treating cancer cells using GEP and/or drug transporter and/or their binding molecules and suppression thereof. Methods of cancer treatment targeting the GEP and/or drug transporters, alone or in combination with chemotherapy are also described herein. Also provided herein are sets of markers whose expression patterns can be used to differentiate clinical conditions, such as high or low levels of GEP and drug transporters. Based on the levels of GEP and drug transporters, the likelihood of cancer recurrences, drug sensitivity, and prognosis can be determined. Methods of classifying and treating patients based on the prognosis are also provided herein. | 11-17-2011 |
| 20110212181 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC RESPIRATORY INFLAMMATION - Neutrophil elastase (NE) is a protease secreted by neutrophils during inflammation. Aberrant expression of NE such as in chronic respiratory inflammatory diseases, results in tissue destruction and decline in lung function. Compositions including an NE-targeting agent that targets the pathologic elements of respiratory inflammation are provided. Non-anticoagulant heparin derivatives or fragments are exemplary NE-targeting agents. The compositions preferably include a carrier, such as chitosan, to facilitate delivery of the active agent. Methods of manufacturing non-anticoagulant heparin are also provided. Methods of administering the disclosed compositions to treat respiratory diseases are also disclosed. In preferred methods, an effective amount of the pharmaceutical composition is administered to subject in need thereof to reduce, inhibit, or alleviate one or more symptoms of chronic respiratory inflammation. In the most preferred embodiment, the composition is administered as a dry powder, intranasally or by inhalation. | 09-01-2011 |
| 20110192455 | BIS-(8-QUINOLINOLATO-N,O)PLATINUM(II) BASED ORGANIC PHOTOVOLTAIC CELL - Organic photovoltaic (OPV) cells and methods of forming the same are provided. An OPV cell can include an organic photoactive layer comprising bis-(8-quinolinolato-N,O)platinum (II) (PtQ | 08-11-2011 |
| 20110150844 | COMPOSITIONS AND METHODS FOR CONTROLLING PROLIFERATION AND DIFFERENTIATION OF CELLS - Methods and compositions for modulating cell differentiation, proliferation and morphology in vitro or in vivo are described. The methods include modifying the extracellular nanoenvironment of stem cells with a self-assembling peptide nanofiber scaffold. The extracellular nanoenvironment can be modified by changing the percentage of self-assembling peptides used to form the nanofiber scaffold, the concentration of cells in the nanofiber scaffold, the pH, or the amounts of serum. Modulating the extracellular nanoenvironment of cells in nanofiber scaffold allows for increased targeting of cell placement and therapeutic delivery, amplified by cell encapsulation and implantation. | 06-23-2011 |
| 20110144023 | Nano Cancer Barrier Device (NCBD) to Immobilize and Inhibit the Division of Metastic Cancer Stem Cells - The present invention provides methods, compositions, and kits wherein nanomaterials are used for inhibiting cancer stem cell division, colony formation, spheroid formation and self-renewal. The present invention also provides methods, compositions, and kits wherein nanomaterials are used for treating cancer, coating tumors, and inhibiting metastasis. The present invention also provides methods, compositions, and kits wherein nanomaterials are used for inducing cells to go into stasis. The present invention further provides methods for isolating tumors, inhibiting bleeding, and marking margins of tumors and organs during surgery with a nanomaterial. | 06-16-2011 |
| 20110135663 | ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The subject invention provides antibodies, or binding fragments thereof, that specifically bind to human IGF-IR. Also provided are nucleic acid molecules encoding the antibodies and binding fragments of the subject invention and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens. | 06-09-2011 |
| 20110098264 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLOMETALATED N-HETEROCYCLIC CARBENE COMPLEXES FOR CANCER TREATMENT - The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase. | 04-28-2011 |
| 20110059378 | CATALYST FOR HYDROGEN GENERATION FROM SMALL ORGANIC MOLECULES - A catalyst for the generation of hydrogen from a small organic molecule comprises a tertiary metal composition where: the first metal is either Pt or Ru; the second metal is at least one of Pt, Ru, Au, Pd, Rh, Ir, Os, and/or Re; and Bi, primarily present in the form of an oxide or of a mixture of oxides and carbonates and in the +3 oxidation state. A portion of the first and/or second metal may be in the form of an oxide. The catalyst can be in the form of a nanoparticle and supported on an inert substrate, such as carbon. The catalyst can be used for dehydrogenation of formic acid or other small organic molecules in a liquid state at ambient pressures and at temperatures below the boiling point of the liquid. The liquid can be an aqueous solution of the small organic molecule. | 03-10-2011 |
| 20100198777 | SEQUENCE ONLINE ANALYTICAL PROCESSING SYSTEM - A sequence online analytical processing (S-OLAP) system | 08-05-2010 |
| 20100092978 | CADHERIN-17 AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCER - Compositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and/or monitoring liver cancers using the expressing of CDH17 involve detecting and/or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor. | 04-15-2010 |
| 20100080824 | HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF - The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences. | 04-01-2010 |
| 20090192990 | Method and apparatus for realtime or near realtime video image retrieval - A distributed absorbing surveillance apparatus comprising a plurality of surveillance branches at which data of a video image frame is characterised, indexed and stored locally in real-time upon capturing means browsing and searching can be conducted locally at a relatively low computational overhead upon receipt of searching instructions from a central query processor. Such a distributed surveillance apparatus also facilitates enhanced target searching speed and efficiency. | 07-30-2009 |
